Adecto Pharmaceuticals

Executive Summary

Adecto Pharmaceuticals is an early-stage biotech developing a novel monoclonal antibody targeting ADAM8-positive solid tumors, particularly those resistant to conventional immunotherapy. Founded in 2019 and based in Cambridge, MA, the company aims to reprogram a broader set of immune cells to generate a more potent anti-cancer response. Currently in pre-clinical stage, Adecto has not disclosed funding rounds or valuation. Its approach addresses an unmet need in aggressive tumors with limited treatment options, though the technology is unvalidated in humans. The company's progress depends on advancing its candidate into IND-enabling studies and securing partnerships or financing to support clinical trials.

Upcoming Catalysts (preview)

• TBDPreclinical proof-of-concept data in ADAM8-positive tumor models50% success
• TBDIND-enabling study initiation and regulatory filing20% success
• TBDStrategic partnership or licensing deal with larger biopharma10% success